GPGI CompoSecure Husky Securities Fraud Class Action
Analysis based on 23 articles · First reported Sep 01, 2026 · Last updated Sep 11, 2026
The lawsuit creates legal and reputational overhang for GPGI, potentially pressuring its stock and raising uncertainty around the Husky acquisition's financial reporting. Broader market impact is limited, as this is a company-specific securities litigation rather than a systemic event.
Multiple investor-rights law firms have filed and publicized a securities class action lawsuit against GPGI, Inc. f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) and certain of its officers. The suit, filed on behalf of purchasers of GPGI Class A common stock between November 3, 2025 and May 6, 2026, alleges violations of federal securities laws. According to the complaints, defendants materially overstated the value of Husky Injection Molding Systems, failed to disclose that Husky was not on track to meet revenue and Adjusted EBITDA targets in the proxy statement, and were primarily motivated by generating millions of dollars in fees for Resolute Holdings and individual defendants rather than creating long-term value for CompoSecure shareholders. The alleged misrepresentations concerned the business, prospects, and expected financial results of GPGI and Husky as a combined business. GPGI's stock reportedly fell 16.36% over two trading sessions after March 12, 2026 earnings disclosure and 25.89% on May 7, 2026 after 1Q26 results and guidance cuts. Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, and Rosen Law Firm have each issued investor alerts reminding class members of the September 14, 2026 lead plaintiff deadline. The case is pending in court and no class has been certified.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard